News

FDA issued a draft guidance to support industry in their development of generic versions of approved opioids with abuse-deterrent formulations (ADF), while ensuring that generic ADF opioids are no less abuse-deterrent than the brand-name drug.

… and solutions from experts

While value-based reimbursement presents opportunities for payers and providers, succeeding in such a reimbursement model can be challenging. Here are four things to strive for that could increase the likelihood of success in a value-based reimbursement model.

While the high cost of specialty pharmacy is no surprise in the healthcare industry, infusibles have additional challenges. Here are the challenges that top the list, and what to do about them.

Find out what causes human error in a healthcare setting, and how to prevent it.

FDA has extended approval of crizotinib (Xalkori, Pfizer) for the treatment of certain patients with non-small cell lung cancer (NSCLC).

In the move to value-based care, there have been surprises and disruptions for payers and providers alike. In this Q&A, an expert shares where we are now.

A month after FDA announced several measures aimed at curbing opioid abuse, the agency said it would require a new boxed warning addressing the serious risk of misuse, abuse, addiction, overdose and death on immediate-release (IR) opioid pain medications.

The new partnership between Walgreens Boots Alliance and OptumRx may signal that Walgreens is not looking to buy another PBM.

As alternative payment models gain traction, payers and providers must take the appropriate steps to thrive.

A diverse group of healthcare stakeholders recently met for CBI's Alternative Payment Models in Healthcare Conference 2016 in Orlando, Florida. Here are five key takeaways from the conference chairman.

Here’s a closer look at what the presidential candidates vow to do if elected to the Oval Office.

Spending on brand name drugs spiked 16.2% in 2015 and 98.2% since 2011, according to a new report from pharmacy benefit manager (PBM) Express Scripts. Plus, a third of branded products experienced price increases greater than 20% in 2015, according to Express Scripts’ annual Drug Trend Report.

The court will consider whether an “accommodation” allowing nonprofit religiously-affiliated organizations to opt out of the ACA requirement that insurance plans include contraception coverage is consistent with the Religious Freedom Restoration Act (RFRA).

Ensuring the appropriate internal investment, addressing key friction points, and taking several steps to increase the likelihood of long-term success is key.

PBM Express Scripts shares findings from its new Drug Trend Report.

An Affordable Care Act payment model is showing that chronically ill patients can be better taken care of in their own homes while bringing down the long-term cost of care.

The Managed Healthcare Executive Editorial Advisory Board says these skills are critical to be a successful healthcare executive today. Do you have what it takes?

During the keynote session at the Advanced Payment Models in Healthcare Conference 2016, PwC experts shared how MACRA legislation will affect reimbursement.

New Health Care Cost Institute analysis examines the value that can be derived from providing cost and quality information for non-emergency healthcare services.

FDA recently approved Idelvion [Coagulation Factor IX (Recombinant), Albumin Fusion Protein] for the treatment of hemophilia B. Here are the top 6 facts to know about Idelvion.

The Centers for Disease Control and Prevention (CDC) issued new voluntary guidelines this week for prescribing opioid medications for chronic pain, excluding cancer, palliative, and end-of-life care.

We asked industry insiders to detail and analyze each component of Trump’s healthcare plan.

Captives can serve as focal points for the captive owners’ collective efforts to promote safer healthcare environments and improved patient outcomes.

US hospitals using rivaroxaban (Xarelto, Janssen Pharmaceuticals) instead of warfarin (Coumadin, Bristol-Myers Squibb) to treat patients diagnosed with a venous thromboembolism (VTE) may save nearly $2,000 per patient and shorten a patient’s hospital stay by approximately 1.5 days, according to a new study.

Agency hits 30% value-based target goal 11 months ahead of schedule.

Surprising way a group of surveyed physicians are saying what they think is the best way to control costs.

Effective teams transform patient and caregiver experience by building trust and meeting goals. Here are five ways how.